secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028048
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q2 net loss $6.4M; cost cuts extend runway into Q1 2024
---------------------------------------------------------------------------

- Net loss of $6.40M ($3.04 per share) vs $2.87M ($2.73) in Q2 2022.
- Cash & equivalents $7.08M at June 30; net cash used in operations $4.47M.
- Cost reduction plan announced to extend financial runway into Q1 2024.
- Multiple USPTO Notices of Allowance for composition of matter claims covering EB-373, EVM201, and EVM301 Series.
- On track to identify EVM301 Series lead candidate by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/0001493152-23-028048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer